Cellectis S.A. (NASDAQ:CLLS) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET
Company Participants
Arthur Stril - Chief Business Officer
Andre Choulika - Chief Executive Officer
Mark Frattini - Chief Medical Officer
Bing Wang - Chief Financial Officer
Conference Call Participants
Gena Wang - Barclays
Jack Allen - Baird
Yigal Nochomovitz - Citigroup
Salveen Richter - Goldman Sachs
David Dai - SMBC
Hartaj Singh - Oppenheimer & Company
Yanan Zhu - Wells Fargo
Ingrid Gafanhao - Kempen
Operator
Greetings, and welcome to the Cellectis Third Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Arthur Stril, Chief Business Officer. Thank you, sir. You may begin.
Arthur Stril
Good morning, and welcome, everyone, to Cellectis' Third Quarter 2022 Corporate Update and Financial Results Conference Call. Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chief Executive Officer; Dr. Bing Wang, our Chief Financial Officer; and Dr. Mark Frattini, our Chief Medical Officer. Yesterday evening, Cellectis filed its interim report and issued a press release reporting its financial results for the third quarter and 9-month period ended September 30th, 2022. The report and press release are available on our website at cellectis.com.
As a reminder, we will make statements regarding Cellectis' financial outlook in addition to its manufacturing, regulatory and product development status and plans and product development of its license partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the SEC and the financial report, including the management report for the year ending on December 31st, 2021, and subsequent filings Cellectis makes with the Securities and Exchange Commission from time to time. I would now like to turn the call over to Andre.
Andre Choulika
Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. 2022 has been a productive year thus far for Cellectis. We have made progress on all fronts that we're thrilled to share with you today. Yesterday, we've announced that our UCART123 abstract was accepted for an oral presentation at the American Society of Ontology's Annual Meeting. We're excited to share preliminary data from AMELI-01 trial, which is a dose escalation and dose expansion study evaluating the safety, expansion, persistence and clinical activity of UCART123 in patients with relapsed or refractory acute myeloid leukemia. Acute myeloid leukemia is a huge unmet medical need with lack of cell therapy options. And these encouraging clinical data are a great step forward for patients. We're also proud that the Amsterdam University Medical Center will present preclinical data at ASH on our product candidate, UCARTCS1, which reinforces the validation of CS1 as the relevant target for relapsed and refractory multiple myeloma patients. Cellectis continues to make progress enrolling patients in its 4 sponsored allogeneic CAR-T trial.